Posts

Posted on

KBW Announces Index Rebalancing for Third-Quarter 2026

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the third quarter of 2026.

This quarter, there are constituent changes within one of our indexes: KBW Nasdaq Regional Banking Index (Index Ticker: KRX)

These changes will be effective prior to the opening of business on Monday, September 21, 2026.

As part of this rebalancing, below are the component-level changes across impacted indices:


KBW Nasdaq Regional Banking Index (Index Ticker: KRX)


Add (1)

: Central Bancompany, Inc. (Nasdaq: CBC)

Several of the KBW Nasdaq indexes have tradable exchange‐traded funds licensed: KBW Nasdaq Bank Index (Index Ticker: BKXSM, ETF Ticker: KBWBSM); KBW Nasdaq Capital Markets Index (Index Ticker: KSXSM); KBW Nasdaq Insurance Index (Index Ticker: KIXSM); KBW Nasdaq Regional Banking Index (Index Ticker: KRXSM); KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDXSM, ETF Ticker: KBWDSM); KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYXSM, ETF Ticker: KBWYSM); KBW Nasdaq Property and Casualty Insurance Index (Index Ticker: KPXSM, ETF Ticker: KBWPSM); KBW Nasdaq Global Bank Index (Index Ticker: GBKXSM); KBW Nasdaq Financial Technology Index (Index Ticker: KFTXSM, ETF Ticker: FTEK.LNSM).

Not all of the listed securities may be suitable for retail investors; in addition, not all of the listed securities may be available to U.S. investors. European investors interested in FTEK LN can contact Invesco at https://etf.invesco.com/gb/private/en/product/invesco-kbw-nasdaq-fintech-ucits-etf-acc/trading-information. U.S. investors cannot buy or hold FTEK LN. An investor cannot invest directly in an index.

About KBW

KBW (Keefe, Bruyette & Woods, Inc., operating in the U.S., and Stifel Nicolaus Europe Limited, also trading as Keefe, Bruyette & Woods Europe, operating in Europe) is a Stifel company. Over the years, KBW has established itself as a leading independent authority in the banking, insurance, brokerage, asset management, mortgage banking and specialty finance sectors. Founded in 1962, the firm maintains industry‐leading positions in the areas of research, corporate finance, mergers and acquisitions as well as sales and trading in equities securities of financial services companies.

Media Contact

Neil Shapiro, (212) 271-3447
[email protected]



Posted on

Skyworks Announces Extension of Expiration Date of Exchange Offers for Qorvo’s Senior Notes due 2029 and 2031

IRVINE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS) (“Skyworks”), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, today announced that it has extended the expiration date of its previously announced offers to holders of Qorvo Notes (as defined herein) to exchange (the “Exchange Offers”) any and all outstanding 4.375% Senior Notes due 2029 (the “2029 Qorvo Notes”) and any and all outstanding 3.375% Senior Notes due 2031 (the “2031 Qorvo Notes” and, together with the 2029 Qorvo Notes, the “Qorvo Notes”) issued by Qorvo, Inc. (“Qorvo”) as set forth in the table below for (1) with respect to the 2029 Qorvo Notes, up to $850,000,000 aggregate principal amount of new 4.375% Senior Notes due 2029 (the “New 2029 Skyworks Notes”) issued by Skyworks and (2) with respect to the 2031 Qorvo Notes, up to $700,000,000 aggregate principal amount of new 3.375% Senior Notes due 2031 (together with the New 2029 Skyworks Notes, the “New Skyworks Notes”) issued by Skyworks.

Extension of Expiration Date

The Expiration Date of the Exchange Offers and the Withdrawal Deadline were previously extended to 5:00 p.m., New York City time, on September 11, 2026.

Skyworks has further extended the Expiration Date and the Withdrawal Deadline to 5:00 p.m., New York City time, on September 18, 2026, subject to further extension or earlier termination or other amendment. Skyworks is hopeful that the Mergers (as defined herein) will close within the calendar year (subject to satisfaction or waiver of all closing conditions) and is preparing to close as early as within the fiscal year. However, there can be no assurances that the closing will occur on this timeline. All other terms and conditions of the Exchange Offers as set forth in the Prospectus (as defined herein) remain in full force and effect. Capitalized terms used but not defined herein have the respective meanings set forth in the Prospectus.

Participation to Date

Global Bondholder Services Corporation, the information agent for the Exchange Offers, has advised Skyworks that as of 5:00 p.m., New York City time, on September 11, 2026, the last business day prior to the announcement of the further extension of the Exchange Offers, the following respective principal amounts of each series of Qorvo Notes have been validly tendered and not validly withdrawn:

Title of Qorvo Notes /

CUSIP / ISIN No. 		Principal Amount Outstanding Principal Amount Tendered Percentage
4.375% Senior Notes due 2029

Registered:

74736KAH4 /
US74736KAH41

144A:
74736KAG6 /
US74736KAG67

Regulation S:
U7471QAF1 /
USU7471QAF10

 $850,000,000 $772,253,000 90.85%
3.375% Senior Notes due 2031

144A:
74736KAJ0 /
US74736KAJ07

Regulation S:
U7471QAJ3 /
USU7471QAJ32

 $700,000,000 $654,035,000 93.43%

Holders of Qorvo Notes who have already validly tendered and not validly withdrawn their Qorvo Notes do not need to re-tender their notes or take any other action as a result of the extension of the Expiration Date, and their tenders remain effective. Holders of Qorvo Notes who have not yet validly tendered, or who validly tendered and validly withdrew, may tender or re-tender, as applicable, their Qorvo Notes at any time at or prior to the Expiration Date and will be eligible to receive the applicable consideration as described in the Prospectus, subject to the terms and conditions set forth in the Prospectus, including, subject to submitting a valid Early Participation VOI Number with respect to such tendered or re-tendered Qorvo Notes, the Early Participation Premium with respect to such Qorvo Notes.

Settlement Date

Subject to the terms and conditions set forth in the Prospectus, the settlement date (the “Settlement Date”) will be promptly after the Expiration Date and is expected to occur no earlier than the second business day after the closing date of the Mergers.

Additional Information

The Exchange Offers are being made pursuant to the terms and subject to the conditions set forth in Skyworks’ registration statement on Form S-4, which was declared effective on May 29, 2026, and the related final prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 29, 2026 (as it may be amended or supplemented from time to time, the “Prospectus”). Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Prospectus. Each Exchange Offer is conditioned upon the closing of the transactions pursuant to which Qorvo will merge with and into a subsidiary of Skyworks (the “Mergers”), with such subsidiary continuing as the surviving entity and a wholly-owned subsidiary of Skyworks, which condition may not be waived by Skyworks. The closing of the Mergers is not conditioned upon the results of the Exchange Offers.

Skyworks, in its sole discretion, may modify or terminate either Exchange Offer and may extend the Expiration Date and/or the Settlement Date with respect to either Exchange Offer, subject to applicable law. Any such modification, termination or extension by Skyworks with respect to an Exchange Offer will not automatically modify, terminate or extend the other Exchange Offer. The Exchange Offer with respect to a series of Qorvo Notes is not conditioned upon the consummation of the Exchange Offer with respect to the other series of Qorvo Notes.

The complete terms and conditions of the Exchange Offers are described in the Prospectus, a copy of which may be obtained by contacting Global Bondholder Services Corporation, the exchange agent and information agent in connection with the Exchange Offers, at (855) 654-2015 (U.S. toll-free) or (212) 430-3774 (banks and brokers) or [email protected]. Questions regarding the terms and conditions of the Exchange Offers should be directed to the dealer manager, Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Collect: (212) 357-1452, Toll-Free: (800) 828-3182.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to purchase or sell, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Exchange Offers are being made solely pursuant to the Prospectus and only to such persons and in such jurisdictions as is permitted under applicable law.

About Skyworks

Skyworks Solutions, Inc. is empowering the wireless networking revolution. Skyworks is a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet and wearables.

Skyworks is a global company with engineering, marketing, operations, sales and support facilities located throughout Asia, Europe and North America and is a member of the S&P 500® market index (Nasdaq: SWKS).

Safe Harbor Statement

This press release includes “forward-looking statements.” Forward-looking statements relate to future events, including, but not limited to, the Exchange Offers and the Mergers, as applicable. These forward-looking statements include information relating to future events, prospects, expectations and results of Skyworks (e.g., certain projections and business trends, including with respect to future sales and revenue, as well as plans for dividend payments). Forward-looking statements can often be identified by words such as “anticipates,” “estimates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. All such statements are subject to certain risks, uncertainties and other important factors that could cause actual results to differ materially and adversely from those projected and may affect Skyworks’ future operating results, financial position and cash flows.

These risks, uncertainties and other important factors include: the risks of doing business internationally, including from trade war or trade protection measures (e.g., tariffs, retaliatory tariffs and other countermeasures or taxes), increased import/export restrictions and controls (e.g., Skyworks’ ability to obtain foreign-sourced raw materials, including from Chinese-based sources, as well as Skyworks’ ability to sell products to certain specified foreign entities only pursuant to a limited export license from the U.S. Department of Commerce), the susceptibility of the semiconductor industry and the markets addressed by Skyworks’, and Skyworks’ customers’, products to economic cycles or changes in economic conditions, including inflation and recession that could result from trade war or trade protection measures; Skyworks’ reliance on a small number of key customers for a large percentage of Skyworks’ sales; decreased gross margins and loss of market share as a result of increased competition; Skyworks’ ability to obtain design wins from customers; Skyworks’ ability to convert design wins into revenue; market acceptance of Skyworks’ products and Skyworks’ customers’ products, including market acceptance of new, emerging technologies such as AI; the mix and volume of phone models sold by Skyworks’ largest customer; the potential impacts on Skyworks’ business, reputation, relationships, results of operations, cash flows and financial condition as a result of the Mergers and related transactions with Qorvo; the possibility that expected benefits related to such transactions with Qorvo may not materialize as expected; such transactions with Qorvo being timely completed, if completed at all; regulatory approvals required for the Mergers and related transactions not being timely obtained, if obtained at all, or being obtained subject to conditions; Skyworks or Qorvo’s business experiencing disruptions as a result of the Mergers and related transactions or due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; Skyworks and Qorvo being unable to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all; the costs, fees, expenses and other charges related to the Mergers and related transactions with Qorvo, including with respect to any related litigation; reduced flexibility in operating Skyworks’ business as a result of the substantial amount of additional indebtedness Skyworks has incurred and expects to incur in connection with the Mergers and related transactions; delays in the deployment of commercial 5G networks or in consumer adoption of 5G-enabled devices; the volatility of Skyworks’ stock price; changes in laws, regulations and/or policies that could adversely affect Skyworks’ operations and financial results, the economy and Skyworks’ customers’ demand for Skyworks’ products, or the financial markets and Skyworks’ ability to raise capital; fluctuations in Skyworks’ manufacturing yields due to Skyworks’ complex and specialized manufacturing processes; Skyworks’ ability to develop, manufacture and market innovative products, avoid product obsolescence, reduce costs in a timely manner, transition Skyworks’ products to smaller geometry process technologies and achieve higher levels of design integration; the quality of Skyworks’ products and any defect remediation costs; Skyworks’ products’ ability to perform under stringent operating conditions; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials, including rare earth and similar minerals, supplier components, equipment and shipping and logistics services, including limits on Skyworks’ customers’ ability to obtain such services and materials; risks that Skyworks may not be able to optimize Skyworks’ manufacturing footprint and achieve any financial and operational benefits from such efforts, including reducing fixed costs or improving utilization rates, disruptions to Skyworks’ manufacturing processes, including relating to any relocation of Skyworks’ key facilities; Skyworks’ ability to successfully manage Skyworks’ senior management transitions; Skyworks’ ability to retain, recruit and hire key executives or the departure of any such executives, technical personnel and other employees in the positions and numbers, with the experience and capabilities, and at the compensation levels needed to implement Skyworks’ business and product plans; the timing, rescheduling or cancellation of significant customer orders and Skyworks’ ability, as well as the ability of Skyworks’ customers, to manage inventory; other economic, social, military and geopolitical conditions in the countries in which Skyworks, Skyworks’ customers or Skyworks’ suppliers operate, including the conflicts in Ukraine, Iran and other regions in the Middle East, possible disruptions in transportation networks, and fluctuations in foreign currency exchange rates; the effects of global health crises on business conditions in Skyworks’ industry, including the risk of significant disruptions to Skyworks’ business operations, as well as negative impacts to Skyworks’ financial condition; Skyworks’ ability to prevent theft of Skyworks’ intellectual property, disclosure of confidential information or breaches of Skyworks’ information technology systems; uncertainties of litigation, including Skyworks’ ongoing securities litigation, potential disputes over intellectual property infringement and rights, as well as payments related to the licensing and/or sale of such rights; Skyworks’ ability to continue to grow and maintain an intellectual property portfolio and obtain needed licenses from third parties; Skyworks’ ability to make certain investments and acquisitions, integrate companies Skyworks acquires and/or enter into strategic alliances; and other risks and uncertainties, including those detailed from time to time in Skyworks’ filings with the Securities and Exchange Commission.

The forward-looking statements contained in this press release are made only as of the date hereof, and Skyworks undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Additional Information about the Mergers and Where to Find It

In connection with the Mergers, Skyworks has filed with the SEC a registration statement on Form S-4, which includes a proxy statement of Qorvo that also constitutes a prospectus for the shares of Skyworks common stock to be offered in the Mergers (collectively, the “Mergers Registration Statement and Proxy Statement/Prospectus”). Each of Skyworks and Qorvo may also file other relevant documents with the SEC regarding the Mergers. This communication is not a substitute for the proxy statement/prospectus or registration statement or any other document that Skyworks or Qorvo may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE MERGERS REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT SKYWORKS, QORVO, THE MERGERS AND RELATED MATTERS.

Investors and security holders can obtain free copies of the Mergers Registration Statement and Proxy Statement/Prospectus and other documents containing important information about Skyworks, Qorvo and the Mergers filed with the SEC through the website maintained by the SEC at www.sec.gov. The documents filed by Skyworks with the SEC also may be obtained free of charge at Skyworks’ website at https://www.skyworksinc.com/investors or upon written request to Skyworks at [email protected]. The documents filed by Qorvo with the SEC also may be obtained free of charge at Qorvo’s website at https://ir.qorvo.com/ or upon written request to Qorvo at [email protected].

Media Relations:

Constance Griffiths
(949) 230-4867
[email protected]		 Investor Relations:

Raji Gill
(949) 508-0973
[email protected]



Posted on

Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PITTSBURGH, Sept. 11, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU) (the “Company”) today announced that it has granted a non-qualified stock option to purchase 60,000 shares of the Company’s common stock to one non-executive individual as an inducement material to the individual’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option was not granted under the Company’s 2024 Equity Incentive Plan.

The stock option has an exercise price of $10.67 per share and a grant date of September 7, 2026. The option has a ten-year term and vests as follows: one-third of the shares subject to the option vest on the one-year anniversary of the grant date, and the remaining shares vest in equal monthly installments over the following twenty-four months, in each case subject to continued service through the applicable vesting date.

About Axe Compute

Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure platform built on a fundamental premise: AI innovation should not be constrained by hardware choice or availability. The company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two core offerings: Axe Compute Access, delivering high-performance GPU infrastructure across global locations, and Axe Compute Build, enabling the design, deployment, ownership, and operation of large-scale, dedicated AI infrastructure worldwide. Axe Compute is headquartered in Pittsburgh, Pennsylvania. For more information, visit axecompute.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements are statements other than statements of historical fact and can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “intend,” “estimate,” “project,” “will,” “may,” “should,” “would,” “could,” “target,” “forecast,” “seek,” “continue,” and similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks described in Axe Compute’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Axe Compute undertakes no obligation to update them, except as required by law.

Media and Investor Relations Contact

Erin McMahon
[email protected]



Posted on

FCPT Declares Fourth Quarter 2026 Monthly Dividends

FCPT Declares Fourth Quarter 2026 Monthly Dividends

MILL VALLEY, Calif.–(BUSINESS WIRE)–Four Corners Property Trust, Inc. (NYSE: FCPT) today announced that its Board of Directors declared monthly cash dividends of $0.1265 per share (equivalent of $1.5180 per share per annum) for the fourth quarter of 2026, payable in cash on the payment dates set forth in the following table to FCPT common stock shareholders of record as of the close of business on the record date. This represents a 3.5% increase from the prior quarter.

Declared Amount

Record Date

Payment Date

$0.1265

October 30, 2026

November 16, 2026

$0.1265

November 30, 2026

December 15, 2026

$0.1265

December 31, 2026

January 15, 2027

About FCPT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the ownership, acquisition and leasing of restaurant and retail properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. Additional information about FCPT can be found on the website at www.fcpt.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include all statements that are not historical statements of fact and those regarding FCPT’s intent, belief or expectations, including, but not limited to, statements regarding: operating and financial performance and expectations regarding the making of distributions and the payment of dividends. Words such as “anticipate(s),” “expect(s),” “intend(s),” “plan(s),” “believe(s),” “may,” “will,” “would,” “could,” “should,” “seek(s)” and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. Forward-looking statements speak only as of the date on which such statements are made and, except in the normal course of FCPT’s public disclosure obligations, FCPT expressly disclaims any obligation to publicly release any updates or revisions to any forward-looking statements to reflect any change in FCPT’s expectations or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are based on management’s current expectations and beliefs and FCPT can give no assurance that its expectations or the events described will occur as described. For a further discussion of these and other factors that could cause FCPT’s future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in FCPT’s most recent annual report on Form 10-K, and other risks described in documents subsequently filed by FCPT from time to time with the Securities and Exchange Commission.

FCPT

Bill Lenehan, 415-965-8031

CEO

Patrick Wernig, 415-965-8038

CFO

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: REIT Restaurant/Bar Retail Commercial Building & Real Estate Construction & Property

MEDIA:

Posted on

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

  • ISEMBYLD is approved for use in all adults and children ≥2 years of age with SMA who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment
  • ISEMBYLD recommended dose of 10 mg/kg showed a robust, clinically meaningful 2.2-point improvement in motor function as measured by the gold-standard Hammersmith Functional Motor Scale-Expanded (HFMSE) compared to placebo, with all patients receiving SMN2-targeted background therapy (p = 0.0121*)
  • ISEMBYLD showed a ≥ 3-point increase in HFMSE in 34.2% of patients compared to 13.5% of patients on placebo (odds ratio 3.8; p = 0.0125*)
  • ISEMBYLD U.S. commercial launch underway with product available to ship in the coming days; Scholar Rock Supports™ dedicated support team now available to assist patients and caregivers
  • Management to host investor call Monday, September 14, 2026, at 8:00 a.m. ET

* nominal p-value

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

SMA is a rare, severe neuromuscular disease that results in irreversible loss of motor neurons and progressive muscle wasting, causing continuous motor function decline throughout life and diminishing the independence of both adults and children.

ISEMBYLD is the first and only muscle-targeted treatment to demonstrate motor function improvement in individuals with SMA currently receiving an SMN2-targeted treatment. In the Phase 3 randomized, placebo-controlled SAPPHIRE study, individuals receiving ISEMBYLD demonstrated a robust, clinically meaningful improvement in motor function after one year of treatment while those on an SMN2-targeted treatment alone experienced a loss of motor function.

“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S.,” said David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock. “After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD. Our U.S. commercial team is now engaging physicians, SMA care teams, and payers on behalf of the SMA community and our Scholar Rock Supports™ team stands ready to provide dedicated, comprehensive assistance to patients and caregivers. I would like to extend my deepest thanks to our clinical study investigators, Cure SMA, and other patient advocacy groups for their dedication and support on this journey. Above all, I want to express my heartfelt gratitude to the patients and families affected by SMA who participated in our clinical trials for their trust in Scholar Rock and unwavering resilience every step of the way.”

“The approval of ISEMBYLDas the first-ever treatment to directly target the muscular component of SMA is a significant turning point for adults and children who have been waiting for innovative therapeutic options to improve motor function,” said Kenneth Hobby, President of Cure SMA. “We appreciate the FDA’s recognition, as reflected in this approval that supports access for a broad population within the SMA community, that improving motor function is a significant unmet need that must be addressed with urgency. Such improvements are fundamental to maintaining independence and to enabling participation in important activities of daily living from self-care to work and social interactions.”

With the approval of ISEMBYLD, Scholar Rock was awarded a Rare Pediatric Disease Priority Review Voucher, which may be used to obtain priority review for a future marketing application.

ISEMBYLD Robust Clinical Efficacy and Safety Profile from Phase 3 SAPPHIRE Study

The approval of ISEMBYLD was based on positive results from the Phase 3 pivotal, randomized, double-blind, placebo-controlled SAPPHIRE study. The SAPPHIRE study met its primary endpoint, and demonstrated a robust, clinically meaningful 2.2-point improvement in the gold-standard Hammersmith Functional Motor Scale-Expanded (HFMSE) in patients receiving ISEMBYLD 10 mg/kg and an SMN2-targeted treatment compared to patients receiving an SMN2-targeted treatment alone at one year (nominal p = 0.0121; main efficacy population 2 – 12 years of age, n = 103). Additionally, 34.2% of ISEMBYLD-treated patients showed a ≥ 3-point increase in HFMSE compared to 13.5% of placebo-treated patients (odds ratio of 3.8; nominal p = 0.0125).

ISEMBYLD has a well-characterized safety profile. The safety database includes more than 500 individuals across all apitegromab clinical studies globally, some of whom have been on treatment for more than 7 years. Ninety-eight percent of participants treated in SAPPHIRE elected to continue in the ONYX long-term extension study. In the SAPPHIRE study, the most common adverse reactions were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity. Fractures occurred in 9% of patients treated with ISEMBYLD 10 mg/kg vs. 2% in placebo.

For further information, see Important Safety Information below.

“Today’s approval of ISEMBYLD marks a new era for the treatment of SMA,” said Dr. Basil Darras, M.D., Associate Neurologist-in-Chief, Director of the Neuromuscular Center and Spinal Muscular Atrophy Program at Boston Children’s Hospital, and a principal investigator in the SAPPHIRE study. “As neurologists, families consistently tell us that their top priority is gaining motor function, and we are now able to directly target the muscle, not just the motor neuron, for people living with SMA.”

ISEMBYLD Commercial Availability and Patient Access

Scholar Rock Supports is now available to assist patients who have been prescribed ISEMBYLD. This program is designed to provide personalized support for patients and families, and includes help to understand insurance coverage, financial assistance programs for eligible patients, and disease and treatment education. Scholar Rock Supports will also help patients and families navigate their site of care options, as well as ongoing infusion logistics. Based on eligibility, infusions can be given at convenient locations including hospital, home, or infusion center. ISEMBYLD will be available to ship in the coming days.

Scholar Rock is working closely with top commercial and government payers to establish reliable, broad access to ISEMBYLD for appropriate patients.

Healthcare providers and patients can learn more about Scholar Rock’s patient support services by visiting www.ScholarRockSupports.com or calling 833-777-5444 (833-SRRK-444). For more information about ISEMBYLD and U.S. Prescribing Information, visit www.ISEMBYLD.com.

Conference Call Information

Scholar Rock will host a conference call and webcast on Monday, September 14, 2026, at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at https://investors.scholarrock.com.

To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.

A replay of the webcast will be available on the Company’s website for approximately 90 days.

About ISEMBYLD

ISEMBYLD is a fully human monoclonal IgG4 antibody that binds to promyostatin and latent myostatin and inhibits the activation of myostatin, blocking myostatin signaling. ISEMBYLD is approved in the United States for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

For more information, visit www.ISEMBYLD.com.

Indication and Important Safety Information

What is ISEMBYLD (apitegromab-mstn)?

ISEMBYLD is a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

IMPORTANT SAFETY INFORMATION

Before taking ISEMBYLD, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of low bone density or bone fractures

  • are pregnant or plan to become pregnant. If you are pregnant or are planning to become pregnant, ask your healthcare provider for advice before taking this medicine. It is not known if ISEMBYLD will harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with ISEMBYLD

  • are breastfeeding or plan to breastfeed. It is not known if ISEMBYLD passes into breast milk. Talk to your healthcare provider about the best way to feed your baby while on treatment with ISEMBYLD

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of them to show your healthcare provider, including your pharmacist, when you get a new medicine.

What are the possible side effects of ISEMBYLD?

  • Fractures. Treatment with ISEMBYLD may increase the risk of bone fractures, including serious fractures. Bone fractures may happen with or without a fall or other injury. Your healthcare provider may consider stopping treatment with ISEMBYLD if you experience a bone fracture during treatment.

The most common side effects of ISEMBYLD include:

  • upper respiratory tract infections

  • vomiting

  • cough

  • viral infections

  • headache

  • stomach flu (gastroenteritis)

  • sore throat (pharyngitis)

  • hypersensitivity

These are not all of the possible side effects of ISEMBYLD. Call your healthcare provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information and Patient Information.

About the SAPPHIRE Clinical Trial

SAPPHIRE (NCT05156320) was a global, multi-national, randomized, double-blind, placebo-controlled Phase 3 clinical trial that evaluated the safety and efficacy of ISEMBYLD (apitegromab-mstn) in a total of 188 patients in 9 countries with a diagnosis of 5q SMA who were 2 to 21 years of age. Patients were randomized in a 1:1:1 ratio to receive ISEMBYLD 20 mg/kg (2 times the recommended dosage), ISEMBYLD 10 mg/kg (the recommended dosage), or placebo, respectively, via intravenous infusion once every 4 weeks for approximately 1 year. All patients enrolled in this trial were receiving an approved SMN2-targeted treatment (either nusinersen or risdiplam).

About SMA

Spinal muscular atrophy (SMA) is a rare, severe, genetic neuromuscular disease. The disease is characterized by the irreversible loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk, and progressive muscle wasting that causes continuous motor function decline throughout life and can diminish the independence of both children and adults. Motor function decline in SMA patients is affected by motor neuron health and muscle responsiveness. SMN-targeted treatments are designed to prevent motor neuron loss but do not directly address muscle. It is estimated that approximately 35,000 SMA patients globally have been treated with an SMN-targeted treatment.

About Scholar Rock

Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Scholar Rock intends to commercialize ISEMBYLD (apitegromab-mstn) globally, beginning in the U.S. for individuals living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark and ISEMBYLD™ is a trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Scholar Rock’s expectations regarding the U.S. commercial launch of ISEMBYLD, ISEMBYLD’s ability to support a broad patient population, the potential approval and launch of apitegromab in other geographies, ISEMBYLD’s ability to change patient lives, the anticipated benefits of ISEMBYLD for patients with SMA, and the Company’s business strategy, plans and prospects. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “anticipate,” “plan,” “believe,” “intend,” “estimate,” “potential,” “continue,” “target,” “goal,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on the Company’s current expectations, intentions, and beliefs regarding future events, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the Company’s ability to successfully commercialize ISEMBYLD in the U.S.; the Company’s ability to obtain and maintain regulatory approval of apitegromab in other jurisdictions; risks related to market acceptance, competition, pricing, reimbursement and access; manufacturing and supply chain risks; Scholar Rock’s ability to obtain, maintain and protect its intellectual property; and Scholar Rock’s dependence on third parties for development and manufacture of ISEMBYLD, as well as those risks more fully discussed in the section entitled “Risk Factors” in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

Multimedia Assets:

https://scholarrock.com/media-kit/ISEMBYLD.jpg

https://scholarrock.com/media-kit/ISEMBYLD_logo.jpg

https://scholarrock.com/media-kit/Scholar_Rock_logo.png

https://scholarrock.com/media-kit/Scholar_Rock_Supports.jpg

Scholar Rock:

Investors

Laura Ekas, Ph.D.

[email protected]

917-439-0374

Media

Jeff Smith

682-401-8428

Molly MacLeod, Ph.D.

802-579-5995

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Research Men Pharmaceutical Consumer Children Clinical Trials Science Women Biotechnology Neurology FDA Health

MEDIA:

Logo
Logo
Posted on

Greenberg Traurig Advises Ryman Hospitality Properties on $1.38B Grande Lakes Orlando Resort Acquisition

PR Newswire

WASHINGTON, Sept. 11, 2026 /PRNewswire/ — Global law firm Greenberg Traurig, LLP represented Ryman Hospitality Properties, Inc. (NYSE: RHP) (Ryman), a lodging real estate investment trust (REIT), in its acquisition of the fee simple interest in Grande Lakes Orlando Resort for approximately $1.38 billion. The transaction closed Sept. 1.

Greenberg Traurig, LLP

Grande Lakes Orlando is a 409-acre luxury resort complex in Orlando, Florida, featuring a 1,010-room JW Marriott, a 582-room Ritz-Carlton, a Greg Norman-designed 18-hole championship golf course, and approximately 320,000 square feet of meeting and event space. 

Grande Lakes will continue to operate under the JW Marriott and Ritz-Carlton brands managed by Marriott International, according to Ryman’s statement.

“It has been a privilege to support Ryman on another important milestone for the company,” Greenberg Traurig Hospitality Practice Co-Chair Samantha Ahuja said. “Grande Lakes Orlando is a premier destination, and this acquisition reflects Ryman’s continued focus on high-quality hospitality and meeting experiences.”

In addition to Ahuja, the Greenberg Traurig deal team was led by Washington, D.C., Shareholder and Hospitality Practice Co-Chair Nelson F. Migdal, New York Real Estate Shareholder Josh Farrell, and Dallas Real Estate Of Counsel Callie Anne White.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm’s broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI “Best of the Best Recommended Law Firm” by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/greenberg-traurig-advises-ryman-hospitality-properties-on-1-38b-grande-lakes-orlando-resort-acquisition-302876661.html

SOURCE Greenberg Traurig, LLP

Posted on

abrdn Asia-Pacific Income Fund, Inc. (FAX) Announces New Managed Distribution Policy and Declares Monthly Distribution

PR Newswire

PHILADELPHIA, Sept. 11, 2026 /PRNewswire/ — abrdn Asia-Pacific Income Fund, Inc. (NYSE American: FAX) (the “Fund”) today announced that its Board of Directors (the “Board”) has approved a managed distribution policy designed to provide shareholders with a transparent distribution framework aligned with the Fund’s net asset value (“NAV”) and long-term return potential.

Aberdeen Investments

Under the new policy, the Fund intends to pay monthly distributions at an annualized rate of 12% of the Fund’s average NAV per share during the prior month. As a result, for the distribution payable on September 30, 2026, to shareholders of record as of September 22, 2026 (ex-dividend date: September 22, 2026), the Fund’s monthly distribution will change from $0.1650 per share to $0.15 per share.

In approving the managed distribution policy, the Board considered the Fund’s investment objectives, portfolio characteristics, market conditions, earnings potential, and long-term return prospects. The Board believes the new policy provides a disciplined and sustainable framework that balances current income with long-term capital preservation and growth potential.

The Fund’s investment objective is to seek current income. The Fund may also achieve incidental capital appreciation. The Fund invests primarily in Asia-Pacific debt securities.

The Board also believes that a NAV-based policy offers flexibility across market conditions, supports the Fund’s ability to capitalize on opportunities in the Asia-Pacific debt markets, and reduces the risk of distributions exceeding long-term earnings capacity.

Future monthly distribution amounts may increase or decrease as they will be based on the Fund’s NAV.

Distributions are expected to be supported primarily by net investment income, supplemented by realized gains and to the extent necessary paid-in-capital, which is a non-taxable return of capital. Final tax characteristics will be determined annually and reported to shareholders. The managed distribution policy does not guarantee any specific distribution amount, yield, or rate of return.

At the end of each calendar year, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of the Fund’s distributions and provide information with respect to its appropriate tax treatment for the prior calendar year. 

The Fund’s distribution policy is subject to modification by the Board at any time, and there can be no guarantee that the policy will continue. You should not draw any conclusions about the Fund’s investment performance from the amount of the distributions.

Important Information

Shares of closed-end funds are listed for trading on national securities exchanges and are bought and sold in the secondary market. The market price of a fund’s shares is determined by supply and demand and may be greater than (a “premium”) or less than (a “discount”) the fund’s net asset value (NAV). A fund’s investment return and principal value will fluctuate, and investors may receive more or less than their original investment upon the sale of shares. There is no assurance that a fund will achieve its investment objective. Past performance is not indicative of future results.

The trading price of a closed-end fund’s shares may be influenced by various factors, including market conditions, investor sentiment, and other external forces, and is not directly controlled by the fund, its Board of Directors, or its investment adviser. As a result, shares may trade at a premium to or discount from NAV at any given time. A premium to NAV may not be sustained, and a discount to NAV may increase or decrease over time. Investors should consider these risks when purchasing or selling closed-end fund shares.

Shareholders whose fund shares trade at a premium to NAV and who participate in the fund’s dividend reinvestment plan should be aware that distributions may be reinvested at prices above NAV, which may adversely affect investment results.

About Aberdeen Investments

Aberdeen Investments Global is the trade name of Aberdeen’s investments business, herein referred to as “Aberdeen Investments” or “Aberdeen”. In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.

Aberdeen Investments is among the world’s largest asset managers, with decades of experience overseeing closed-end funds dating back to the 1980s. As of June 30, 2026, the firm had approximately $527 billion in assets under management. Closed-end funds represent a core component of Aberdeen Investments’ client franchise in both the U.S. and global markets. Aberdeen and its affiliates currently manage 28 closed-end funds – 17 available in the U.S. and 11 outside the U.S. – totaling $28.3 billion in assets as of June 30, 2026.

          abrdn Asia-Pacific Income Fund, Inc. | Aberdeen

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abrdn-asia-pacific-income-fund-inc-fax-announces-new-managed-distribution-policy-and-declares-monthly-distribution-302876710.html

SOURCE abrdn Asia-Pacific Income Fund, Inc.

Posted on

Alarum Technologies, Ltd. (ALAR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

LOS ANGELES, Sept. 11, 2026 /PRNewswire/ — Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Alarum Technologies, Ltd.

GPWR

IF YOU SUFFERED A LOSS ON YOUR ALARUM TECHNOLOGIES, LTD. INVESTMENTS, CLICK

HERE 
BEFORE OCTOBER 5, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About? 
The complaint filed in this class action alleges that between March 20, 2025 and July 2, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) An Alarum Technologies subsidiary, NetNut, was engaging in illegal activity by linking customer home internet devices into another network without the customers consent; (2) This activity allows cyber criminals to conceal their locations; (3) The foregoing materially heightened Alarum Technologies legal exposure and materially threatened its business prospects; and (4) As a result, defendants statements about Alarum Technologies business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

What’s The Next Step?

Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist you in potentially pursuing claims to recover your loss.

If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. Please contact us to learn more about your rights and interests by clicking here, by email ([email protected]), or by telephone at 310-201-9150 (Toll-Free: 888-773-9224).

You may retain counsel of your choice. If you bought securities during the class period, you may take no action and remain an absent class member. No class has been certified yet.

Why Glancy Prongay Wolke & Rotter LLP? 
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked 2nd in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Glancy Prongay Wolke & Rotter LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected] 
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alarum-technologies-ltd-alar-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302875186.html

SOURCE Glancy Prongay Wolke & Rotter LLP

Posted on

abrdn Healthcare Opportunities Fund (THQ) and abrdn World Healthcare Fund (THW) Announce New Managed Distribution Policies and Declare Monthly Distributions

PR Newswire

PHILADELPHIA, Sept. 11, 2026 /PRNewswire/ — abrdn Healthcare Opportunities Fund (NYSE: THQ) and abrdn World Healthcare Fund (NYSE: THW) (each a “Fund” and together, the “Funds”) today announced that the Board of Trustees (the “Board”) has approved managed distribution policies designed to provide shareholders with transparent distribution frameworks aligned with each Fund’s net asset value (“NAV”) and long-term return potential.

Aberdeen Investments

Under the new policies, each Fund intends to make monthly distributions at an annualized rate of 10% of its average NAV per share during the preceding calendar month. Accordingly, the monthly distributions payable on September 30, 2026, to shareholders of record as of September 22, 2026 (ex-dividend date: September 22, 2026), will change:

  • from $0.1800 per share to $0.17 per share for THQ
  • from $0.1167 per share to $0.12 per share for THW

In approving the policies, the Board considered each Fund’s investment objectives, portfolio characteristics, market conditions, earnings potential and long-term return prospects. The Board believes the new policy provides a disciplined and sustainable framework that balances current income with long-term capital preservation and growth potential.

Each Fund’s investment objective is to seek current income and long-term capital appreciation. The Funds invest primarily in securities of healthcare companies.

The Board also believes the new policies offer flexibility across market conditions and support the Funds’ ability to pursue opportunities in the healthcare sector.

Distributions are expected to be supported primarily by net investment income, supplemented by realized gains and to the extent necessary paid-in-capital, which is a non-taxable return of capital. Final tax characteristics will be determined annually and reported to shareholders. The managed distribution policies do not guarantee any specific distribution amount, yield, or rate of return.

At the end of each calendar year, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of each Fund’s distributions and provide information with respect to its appropriate tax treatment for the prior calendar year. 

The Funds’ distribution policies are subject to modification by the Board at any time, and there can be no guarantee that the policies will continue. You should not draw any conclusions about either Fund’s investment performance from the amount of the distributions.

Important Disclosure

The abrdn Healthcare Opportunities Fund (THQ) and abrdn World Healthcare Fund (THW) today announced that the monthly distributions payable on September 30, 2026, to shareholders of record as of September 22, 2026 (ex-dividend date: September 22, 2026), will be $0.17 per share for THQ and $0.12 per share for THW.

Under applicable U.S. tax rules, the amount and character of distributable income for each Fund’s fiscal year can be finally determined only as of the end of the Fund’s fiscal year. However, under Section 19 of the Investment Company Act of 1940, as amended (the “1940 Act”) and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to shareholders.

The following tables set forth the estimated amounts of the sources of the distributions for purposes of Section 19 of the 1940 Act and the rules adopted thereunder. The tables have been computed based on generally accepted accounting principles.  The tables include estimated amounts and percentages for the current distributions to be paid as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses on securities and currencies.

The Funds’ estimated sources of the current distributions to be paid and for its current fiscal year to date are as follows:


Estimated Amounts of Current Distribution per Share


Fund


Distribution
Amount


Net Investment
Income


Net Realized Short-Term
Gains*


Net Realized Long-
Term Gains


Return of
Capital

THQ

$0.1700

–

–

$0.0765

45 %

$0.0731

43 %

$0.0204

12 %

THW

$0.1200

–

–

$0.0696

58 %

$0.0504

42 %

–

–

 


Estimated Amounts of Fiscal Year to Date Cumulative Distributions per Share


Fund


Fiscal Year**
to Date
Distribution
Amount


Net Investment
Income


Net Realized Short-Term
Gains*


Net Realized Long-
Term Gains


Return of
Capital

THQ

$2.1500

–

–

$0.9675

45 %

$0.9245

43 %

$0.2580

12 %

THW

$1.4037

–

–

$0.8141

58 %

$0.5896

42 %

–

–

* includes currency gains

** THQ and THW have a 9/30 fiscal year end.

Where the estimated amounts above show a portion of the distribution to be a “Return of Capital,” it means that Fund estimates that it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income.”

The amounts and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations. After the end of each calendar year, a Form 1099-DIV will be sent to shareholders for the prior calendar year that will tell you how to report these distributions for federal income tax purposes.

The following table provides the Funds’ total return performance based on net asset value (NAV) over various time periods compared to the Funds’ annualized and cumulative distribution rates.


Fund Performance and Distribution Rate Information

Fund

Average Annual Total
Return on NAV for the
5-Year Period Ending
8/31/2026¹

Current Fiscal Period’s
Annualized
Distribution Rate on
NAV²

Cumulative Total
Return on NAV¹

Cumulative
Distribution Rate on
NAV²

THQ

4.91 %

10.71 %

25.39 %

9.82 %

THW

8.87 %

9.93 %

22.64 %

9.10 %


1 Return data is net of all fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund’s dividend reinvestment plan.


2 Based on the Fund’s NAV as of August 31, 2026.

Shareholders should not draw any conclusions about a Fund’s investment performance from the amount of the Fund’s current distributions or from the terms of the distribution policy (the “Distribution Policy”).

While NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market.

Pursuant to an exemptive order granted by the Securities and Exchange Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940 Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment in company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held at the date such amount is received.

The payment of distributions in accordance with the Distribution Policy may result in a decrease in the Fund’s net assets. A decrease in the Fund’s net assets may cause an increase in the Fund’s annual operating expense ratio and a decrease in the Fund’s market price per share to the extent the market price correlates closely to the Fund’s net asset value per share. The Distribution Policy may also negatively affect the Fund’s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund’s Board has the right to amend, suspend or terminate the Distribution Policy at any time.

The amendment, suspension or termination of the Distribution Policy may affect the Fund’s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular circumstances.

Circular 230 disclosure:  To ensure compliance with requirements imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.

Important Information

Shares of closed-end funds are listed for trading on national securities exchanges and are bought and sold in the secondary market. The market price of a fund’s shares is determined by supply and demand and may be greater than (a “premium”) or less than (a “discount”) the fund’s net asset value (NAV). A fund’s investment return and principal value will fluctuate, and investors may receive more or less than their original investment upon the sale of shares. There is no assurance that a fund will achieve its investment objective. Past performance is not indicative of future results.

The trading price of a closed-end fund’s shares may be influenced by various factors, including market conditions, investor sentiment, and other external forces, and is not directly controlled by the fund, its Board of Directors, or its investment adviser. As a result, shares may trade at a premium to or discount from NAV at any given time. A premium to NAV may not be sustained, and a discount to NAV may increase or decrease over time. Investors should consider these risks when purchasing or selling closed-end fund shares.

Shareholders whose fund shares trade at a premium to NAV and who participate in the fund’s dividend reinvestment plan should be aware that distributions may be reinvested at prices above NAV, which may adversely affect investment results.

About Aberdeen Investments

Aberdeen Investments Global is the trade name of Aberdeen’s investments business, herein referred to as “Aberdeen Investments” or “Aberdeen”. In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.

Aberdeen Investments is among the world’s largest asset managers, with decades of experience overseeing closed-end funds dating back to the 1980s. As of June 30, 2026, the firm had approximately $527 billion in assets under management. Closed-end funds represent a core component of Aberdeen Investments’ client franchise in both the U.S. and global markets. Aberdeen and its affiliates currently manage 28 closed-end funds – 17 available in the U.S. and 11 outside the U.S. – totaling $28.3 billion in assets as of June 30, 2026.

          abrdn Healthcare Opportunities Fund | Aberdeen
          abrdn World Healthcare Fund | Aberdeen

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abrdn-healthcare-opportunities-fund-thq-and-abrdn-world-healthcare-fund-thw-announce-new-managed-distribution-policies-and-declare-monthly-distributions-302876709.html

SOURCE Aberdeen Investments U.S. Closed-End Funds

Posted on

abrdn Income Credit Strategies Fund (ACP) Announces Change to Monthly Distribution Expected to Be Maintained for at Least the Next 12 Months

PR Newswire

PHILADELPHIA, Sept. 11, 2026 /PRNewswire/ — abrdn Income Credit Strategies Fund (NYSE: ACP) (the “Fund”) announced today that it has reduced its monthly distribution from $0.0775 to $0.055 per common share, beginning with the distribution payable September 30, 2026, to shareholders of record on September 22, 2026 (ex-dividend date: September 22, 2026).

Aberdeen Investments

The revised distribution represents an annualized rate of approximately 12.5% of the Fund’s net asset value as of September 10, 2026. The Fund intends to maintain this distribution level for at least the next 12 months unless there are significant and unforeseen changes in market conditions.

The Fund’s distribution policy is intended to provide investors with a stable monthly distribution consisting of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.

In recommending the revised distribution level, the Fund’s investment adviser (the “Adviser”) considered a range of factors, including current market conditions, expected return opportunities across the credit markets, portfolio earnings, and the broader economic outlook. While the Adviser remains optimistic on both the near-term and long-term prospects for the high yield market, it believes that shareholder distributions should be evaluated in the context of the return opportunities available in today’s market environment.

In approving the new distribution rate, the Board of Trustees (the “Board”) considered a number of factors, including but not limited to, the Fund’s investment objective and strategy and the Adviser’s outlook for credit markets. It was determined that a lower distribution is appropriate because tighter credit spreads have moderated prospective total returns from the elevated levels available in prior years. Relative to broader credit markets, the Adviser remains optimistic regarding both the near-term and long-term prospects for the high yield asset class and believes that asset class continues to be supported by an attractive level of income generation and the potential for capital appreciation.

The revised distribution aligns shareholder payments more closely with the current opportunity set while maintaining ACP’s commitment to providing a differentiated level of income to shareholders. Even after the adjustment, the Fund is expected to offer a distribution rate that remains highly competitive relative to its peer group. The revised distribution provides the portfolio management team with greater flexibility to allocate capital based on the most attractive risk-adjusted opportunities available and to pursue investment decisions that are aligned with the long-term interests of shareholders.

At the end of each calendar year, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of the Fund’s distributions and provide information with respect to its appropriate tax treatment for the prior calendar year.

The Fund’s distribution policy is subject to modification by the Board at any time, and there can be no guarantee that the policy will continue. You should not draw any conclusions about the Fund’s investment performance from the amount of the distributions.

Important Information
Shares of closed-end funds are listed for trading on national securities exchanges and are bought and sold in the secondary market. The market price of a fund’s shares is determined by supply and demand and may be greater than (a “premium”) or less than (a “discount”) the fund’s net asset value (NAV). A fund’s investment return and principal value will fluctuate, and investors may receive more or less than their original investment upon the sale of shares. There is no assurance that a fund will achieve its investment objective. Past performance is not indicative of future results.

The trading price of a closed-end fund’s shares may be influenced by various factors, including market conditions, investor sentiment, and other external forces, and is not directly controlled by the fund, its Board of Directors, or its investment adviser. As a result, shares may trade at a premium to or discount from NAV at any given time. A premium to NAV may not be sustained, and a discount to NAV may increase or decrease over time. Investors should consider these risks when purchasing or selling closed-end fund shares.

Shareholders whose fund shares trade at a premium to NAV and who participate in the fund’s dividend reinvestment plan should be aware that distributions may be reinvested at prices above NAV, which may adversely affect investment results.

About Aberdeen Investments
Aberdeen Investments Global is the trade name of Aberdeen’s investments business, herein referred to as “Aberdeen Investments” or “Aberdeen”. In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.

Aberdeen Investments is among the world’s largest asset managers, with decades of experience overseeing closed-end funds dating back to the 1980s. As of June 30, 2026, the firm had approximately $527 billion in assets under management. Closed-end funds represent a core component of Aberdeen Investments’ client franchise in both the U.S. and global markets. Aberdeen and its affiliates currently manage 28 closed-end funds – 17 available in the U.S. and 11 outside the U.S. – totaling $28.3 billion in assets as of June 30, 2026.

abrdn Income Credit Strategies Fund | Aberdeen 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abrdn-income-credit-strategies-fund-acp-announces-change-to-monthly-distribution-expected-to-be-maintained-for-at-least-the-next-12-months-302876708.html

SOURCE abrdn Income Credit Strategies Fund